Table 3.

Ethnicity and adverse events

	White			Black			Hispanic			Asian
Adverse events	No.	%	P	No.	%	P	No.	%	P	No.	%	P
2891 de novo patients
Induction death	31	5.6	.227	6	6.4	.936	13	11.4	.036	0	0	.637
Induction failure	86	15.4	.925	14	14.9	.980	19	16.7	.846	3	12.0	>.999
Relapse	187	33.5	.625	40	42.6	.113	35	30.7	.637	8	32.0	.952
Death in remission	50	9.0	.937	11	11.7	.514	8	7.0	.624	3	12.0	.489
Secondary malignancy	1	0.2	.209	1	1.1	.268	0	0	1.000	1	4.0	.084
None	203	36.4	.131	22	23.4	.020	39	34.2	.739	10	40.0	.876
2961 de novo patients
Induction death	49	8.4	.020	9	10.7	.620	25	15.9	.008	3	11.5	.841
Induction failure	62	10.6	.255	7	8.3	.648	13	8.3	.472	1	3.8	.505
Relapse	168	28.8	.482	34	40.5	.041	43	27.4	.801	7	26.9	.990
Death in remission	36	6.2	.713	7	8.3	.606	10	6.4	.923	2	7.7	.673
Secondary malignancy	3	0.5	>.999	0	0	>.999	1	0.6	>.999	0	0	>.999
None	265	45.5	.110	27	32.1	.029	65	41.4	.414	13	50.0	.799